TBIO - Telesis Bio Company Cash Volume

Corporate emblem and logo of telesisbio.com (TBIO)

Telesis Bio, Inc. (TBIO) operations are strictly regulated by FDA standards for biomaterial disposal. Its monopoly status in the benchtop gene synthesis sector allows the company to flexibly manage the pricing of BioXp systems. This cash accumulation chart visualizes liquidity, while 0.01 marks a new level. Business progress relies on the implementation of automated solutions and the regular updating of chemical reagents in laboratories.

Telesis Bio, Inc - TBIO Company Liquid Assets (period 04/28/2023 - 10/05/2024)

Analytical breakdowns for Telesis Bio (TBIO)

- stock value and consensus price forecast:
Basic company analysis:TBIO Telesis Bio Inc.
Brand item of telesisbio.com

Liquidity volume determines the degree of business autonomy and its ability to operate without incurring expensive external debt. This metric measures real-time equity sufficiency, allowing for an assessment of management's resource allocation efficiency. By analyzing current cash reserves, an investor can identify the financial buffer available to cover operating expenses. For Telesis Bio, Inc. (TBIO), this is critical when adhering to strict FDA regulations regarding biomaterial disposal. A stable cash balance ensures the continuity of clinical trials.

Competitors of Telesis Bio, Inc. (TBIO)

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|ocugen.com - Company Cash Volume|PACB - Company Cash Volume|BNTC: Company Cash Volume|Company Cash and Cash Equivalents DSGN|Company Cash Funds Rocket Pharmaceuticals|Company Cash on Hand 4DMT (FDMT)|Company Cash Volume LXEO|Company Liquid Assets Korro Bio Inc.|Company Cash Volume EDIT (Editas Medicine Inc)|SLN: Company Cash and Cash Equivalents|PRQR - Company Cash Funds|Company Liquid Assets codexis.com CDXS|SGMO: Company Cash Volume|Nautilus Biotechnology (NAUT) - Company Cash Volume|Company Cash Funds Metagenomi, Inc|precisionbiosciences.com (DTIL) - Company Liquid Assets|Company Cash Funds Generation Bio Co. (GBIO)|Company Liquid Assets Boundless Bio, Inc.|Company Cash Funds Exicure, Inc. XCUR|IMNN: Company Cash and Cash Equivalents|PHIO - Company Cash Funds|Company Liquid Assets Mustang Bio MBIO|RNAZ: Company Cash Volume|Company Cash Position Bionano Genomics Inc. BNGO|APDN (Applied DNA Corp) - Company Cash Volume|bluebirdbio.com (BLUE) - Company Liquid Assets|Company Cash Volume IPA|Company Cash Volume Omega (OMGA)|Company Cash Funds Singular Genomics Systems Inc OMIC|Company Cash Volume Regulus RGLS|syros.com - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume